Harmony Biosciences Holdings, Inc. (HRMY) stock
HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 18/3039% below fair value
$33.11+0.10 (+0.30%)
Close on Nov 18, 2026Market cap $1.93BP/E 10.7Yield –
Harmony Biosciences pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Harmony Biosciences's pe ratio was 11.1× on Nov 11, 2026, against 11.1× a year earlier. Over the last 5 years it ranged from 7.2× to 213.3×, with a median of 13.2×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 11.1× | −0.7 |
| 2025 | Dec 31, 2025 | 11.8× | −4.5 |
| 2024 | Dec 31, 2024 | 16.3× | +3.2 |
| 2023 | Dec 29, 2023 | 13.1× | −8.4 |
| 2022 | Dec 30, 2022 | 21.5× | −191.8 |
| 2021 | Dec 31, 2021 | 213.3× | – |
See a number that looks wrong?